Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Century Therapeutics, Inc. (IPSC)

$2.11 -2.76% NASDAQ: IPSC · 15-min delayed
  • PHILADELPHIA, Pennsylvania
  • Public · NASDAQ: IPSC
  • 78 employees
$384.2MMarket cap
$109.2MRevenue · FY2025
-$9.6MNet income
78Employees
IPSCNASDAQ
2021IPO

About Century Therapeutics, Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$109.2M
Net income
-$9.6M
Total assets
$223.7M
Market cap
$384.2M
Operating margin
-15.8%
Net margin
-8.8%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$109.2M
Operating expenses
$126.4M
Operating income
-$17.3M
Income tax
-$68.0K
Net income
-$9.6M
EPS (basic)
$-0.14
EPS (diluted)
$-0.14

Balance sheet

Total assets
$223.7M
Current assets
$120.8M
Total liabilities
$64.8M
Current liabilities
$20.2M
Shareholders’ equity
$158.9M

Cash flow

Operating cash flow
-$103.9M
Investing cash flow
$107.5M
Financing cash flow
$173.0K
Net cash flow
$3.8M

Statements via Polygon.io (SEC filings)

NASDAQ: IPSC
$2.11 -2.76%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.46 $2.94

52-week range

Market cap
$384.2M
EPS (diluted)
$-0.14
Shares outstanding
182.1M
Open
Day range
Prev close
Volume
IPO date
Jun 18, 2021

Century Therapeutics, Inc. (IPSC) Stock Price

  • Reported a net loss of $9.6M in FY2025.
  • Trading 28% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Century Therapeutics, Inc..

Write a review
Newsroom

News about Century Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Century Therapeutics, Inc.: frequently asked questions

Is Century Therapeutics, Inc. an American company?

Century Therapeutics, Inc. is a US-based company headquartered in Philadelphia, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Century Therapeutics, Inc. headquartered?

Century Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States.

Is Century Therapeutics, Inc. publicly traded?

Yes — Century Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol IPSC on the NASDAQ.

What does Century Therapeutics, Inc. do?

Century Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →